A dose-finding study of duloxetine based on serotonin transporter occupancy

被引:87
作者
Takano, A
Suzuki, K
Kosaka, J
Ota, M
Nozaki, S
Ikoma, Y
Tanada, S
Suhara, T
机构
[1] Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, Chiba 2638555, Japan
[2] Natl Inst Radiol Sci, Dept Med Imaging, Inage Ku, Chiba 2638555, Japan
关键词
duloxetine; occupancy; 5-HTT; PET; DASB; time-course;
D O I
10.1007/s00213-005-0304-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Positron emission tomography (PET) has been utilized for determining the dosage of antipsychotic drugs. To evaluate the dosage of antidepressants such as selective serotonin reuptake inhibitors, serotonin transporter occupancy (5-HTT) is also a useful index. Objectives: We investigated the degree of 5-HTT occupancy with different doses of the antidepressant duloxetine and the time-course of 5-HTT occupancy using PET. Methods: PET scans with [C-11]DASB were performed before and after a single administration of duloxetine (5-60 mg), and three consecutive scans were performed after a single dose or repeated doses of 60 mg of duloxetine. Results: 5-HTT occupancies by duloxetine were increased by 35.3 to 86.5% with dose and plasma concentration increments. The ED50 value of 5-HTT occupancy was 7.9 mg for dose and 3.7 ng/ml for plasma concentration. In the time-course of 5-HTT occupancy, mean occupancies were 81.8% at 6 h, 71.9% at 25 h, and 44.9% at 53 h after a single administration, and 84.3% at 6 h, 71.9% at 49 h, and 47.1% at 78 h after repeated administrations. Conclusions: Based on 5-HTT occupancy, 40 mg and more of duloxetine was needed to attain 80% occupancy, and 60 mg of duloxetine could maintain a high level of 5-HTT occupancy with a once-a-day administration schedule.
引用
收藏
页码:395 / 399
页数:5
相关论文
共 28 条
[1]   Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-lA receptors in the human brain [J].
Andrée, B ;
Hedman, A ;
Thorberg, SO ;
Nilsson, D ;
Halldin, C ;
Farde, L .
PSYCHOPHARMACOLOGY, 2003, 167 (01) :37-45
[2]   Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies [J].
Brannan, SK ;
Mallinckrodt, CH ;
Detke, MJ ;
Watkin, JG ;
Tollefson, GD .
JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (02) :161-172
[3]   Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder [J].
Brannan, SK ;
Mallinckrodt, CH ;
Brown, EB ;
Wohlreich, MM ;
Watkin, JG ;
Schatzberg, AF .
JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (01) :43-53
[4]   Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors [J].
Bymaster, FP ;
Dreshfield-Ahmad, LJ ;
Threlkeld, PG ;
Shaw, JL ;
Thompson, L ;
Nelson, DL ;
Hemrick-Luecke, SK ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (06) :871-880
[5]   Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study [J].
Chalon, SA ;
Granier, LA ;
Vandenhende, FR ;
Bieck, PR ;
Bymaster, FP ;
Joliat, MJ ;
Hirth, C ;
Potter, WZ .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (09) :1685-1693
[6]   Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression [J].
Detke, MJ ;
Lu, YL ;
Goldstein, DJ ;
McNamara, RK ;
Demitrack, MA .
JOURNAL OF PSYCHIATRIC RESEARCH, 2002, 36 (06) :383-390
[7]   Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial [J].
Detke, MJ ;
Lu, YL ;
Goldstein, DJ ;
Hayes, JR ;
Demitrack, MA .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :308-315
[8]   Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial [J].
Detke, MJ ;
Wiltse, CG ;
Mallinckrodt, CH ;
McNamara, RK ;
Demitrack, MA ;
Bitter, I .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (06) :457-470
[9]  
FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71
[10]   Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter:: Modeling strategies [J].
Ginovart, N ;
Wilson, AA ;
Meyer, JH ;
Hussey, D ;
Houle, S .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (11) :1342-1353